![]() ![]() No representation is made as to the safety or effectiveness of 4D-150, 4D-710, 4D-310, 4D-125, or 4D-110 for the therapeutic uses for which they are being studied.ĤD Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT. 4D-150, 4D-710, 4D-310, 4D-125, and 4D-110 are our product candidates in clinical development and have not yet been approved for marketing by the US FDA or any other regulatory authority. The 4D preclinical product candidates in development are: 4D-175 for geographic atrophy and 4D-725 for AATLD.ĤD-150, 4D-710, 4D-310, 4D-125, and 4D-110 are our product candidates in clinical development and have not yet been approved for marketing by the US FDA or any other regulatory authority. 4DMT is currently advancing five product candidates in clinical development: 4D-150 for wet AMD and DME, 4D-710 for cystic fibrosis lung disease, 4D-310 for Fabry disease cardiomyopathy, 4D-125 for XLRP, and 4D-110 for choroideremia. The 4DMT customized and evolved vectors were invented with the goal of being delivered at relatively low doses through clinically routine, well-tolerated, and minimally invasive routes of administration, transducing diseased cells in target tissues efficiently, having reduced immunogenicity and, where relevant, having resistance to pre-existing antibodies. The Company is initially focused on five clinical-stage product candidates in three therapeutic areas for both rare and large market diseases: ophthalmology, pulmonology, and cardiology. All of our vectors are proprietary to 4DMT and were invented at 4DMT, including the vectors utilized in our clinical-stage and preclinical pipeline product candidates: R100, A101, and C102. 4DMT seeks to unlock the full potential of genetic medicines using its proprietary invention platform, Therapeutic Vector Evolution, which combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences to invent customized and evolved vectors for use in our product candidates. ĤDMT is a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic medicines targeting large market diseases. Goldman Sachs Global Healthcare Conference Fireside Chat Date:Īrchived copies of the webcasts will be available for up to one year by visiting the “Investors” section of the 4DMT website at. Jefferies Global Healthcare Conference Fireside Chat Date: (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic medicines targeting large market diseases, announced today it will participate in the following upcoming investor conferences: The company intends to present additional interim data at a CF medical conference in November.EMERYVILLE, Calif., J(GLOBE NEWSWIRE) - 4D Molecular Therapeutics, Inc. 4D-710 is intended to achieve CFTR expression within lung airway epithelial cells, according to the company.ĤD said that plans to initiate a Phase 2 dosing expansion stage during the second half of 2023. The company added that bronchoscopy sample results showed "widespread and consistent expression" of the CFTR transgene protein in 92-99% of lung airway cells "at levels significantly above normal control lung tissue."Īn inherited disease, cystic fibrosis is caused by mutations in the CFTR gene. Just after market close, 4D said that interim data from a small study showed CF patient who were administered an aerosolized formulation of 4D-710 exhibited "meaningful improvement" in CF-related quality of life. No representation is made as to the safety or effectiveness of 4D-150, 4D-310, 4D-710, 4D-125, and 4D-110 for the therapeutic use for which they are being studied. The stock finished the regular session down 5% at $18.27. Shares of 4D were up 21% at $22.12 at around 4:50 p.m. 4D Molecular Therapeutics ( NASDAQ: FDMT) stock rallied 21% in after-hours trading Wednesday after the company released promising interim data from a Phase 1/2 study for its gene therapy 4D-710 for the treatment of cystic fibrosis lung disease.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |